- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Linda Stein Gold, MD, Talks Psoriasis in 2022
Author(s):
Linda Stein Gold, MD, discusses psoriasis in 2022, in her presentation at the current Maui Derm for Dermatologists meeting.
Psoriasis was a hot topic at the current Maui Derm for Dermatologist meeting, held in Maui, Hawaii. In the presentation, “Psoriasis Update: 2022” Linda Stein Gold, MD, director of clinical research and division head of the Department of Dermatology at Henry Ford Hospital in Detroit, Michigan, discussed the challenges in mild to moderate psoriasis, including exciting oral and topical therapies.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Utility of Head-to-Head Studies in Psoriasis Management
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
One-Stop Shop: RAD Offers Comprehensive Insights Into AD Diagnosis, Treatment, and Research
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Related Content
